Lutz Hegemann oversees Corporate Global Strategy, the ESG Management Office and the Global Health organisation of Novartis. This includes group’s business in sub-Saharan Africa as well as the Novartis Foundation. Prior to this, he served as Chief Operating Officer for Global Health, where he led drug discovery, development and delivery for the flagship programmes (malaria, leprosy, sickle cell disease and Chagas disease) and the implementation of the Novartis Access Principles across the portfolio. He has held leadership positions of increasing responsibility since joining Novartis in 2005. In 2011, he was appointed Development Unit Head for Established Medicines & Anti-infectives in the Pharma Division and served on the Development Committee of Novartis.